Kevin has over 25 years of corporate development experience across established biotechnology companies, such as Agouron Pharmaceuticals and Gilead, and venture-backed start-ups, notably, Achillion Pharmaceuticals, Ambrx Biopharma and Plexium. Kevin’s transactional experience includes platform and asset-based collaboration and license agreements as well as mergers and acquisitions.

• 

  Chief Business Officer (CBO) in Arpeggio Bio

  Network biology meets drug discovery